View navigation

For Industry

For Industry


York and Scarborough Teaching Hospitals NHS Foundation Trust has a long history of working with Industry and Clinical Research Organisations (CROs) to deliver research studies successfully and to a high standard.

We are committed to having an Industry portfolio that is appropriate in both complexity and variety to march our Trust's geographical population and size.  Most of the studies we participate in take place at our three larger hospital sites: York Hospital, Scarborough General Hospital and Bridlington District Hospital.

We have collaborated with Industry on Phase II to Phase V studies and each year we continue to build upon out performance and portfolio.

  • In 2024, a 1st European participant was recruited to a commercial oncology study. 
  • 2023 saw us recruit the 1st Global participant to a commercial renal study.
  • 2022 allowed the Trust to bring a paediatric RSV vaccine trial to York and surrounding areas.
  • 2022 build links to our local GP practice network allowing for more commercial research to take place in the region.
  • 2022 a Commercial Research Manager joined the team who continues to build lasting links with Industry partners and develop our portfolio further.
  • 2021 saw us embark on our first large scale Phase II commercial vaccine trial.
  • 2019 saw our Trust successfully gain HSE Class 1 premises clearance to enable us to run studies involving Genetically Modified Organisms.

Industry acknowledgements and notable achievements

  • Over the past 6 years we have had one Global 1st, a European 1st and five UK 1st recruits to commercial studies
  • Over the past 5 years the Trust has Sponsored 7 Industry funded or supported, single and multicenter studies in the following areas: Ophthalmology, Perioperative care and ICU, Dentistry and Gastroenterology.
  • Successful delivery of the Phase 3 COVID-19 vaccine trial COVLP-021, recruiting to target with 54 healthy volunteers. Utilised local and regional media to support the campaign, and delivered at a newly setup, trial-specific Vaccine Hub at the University of York by the R&D Department.
  • Our participation in Arquer 006 contributed to the recruitment of 84 patients across North Yorkshire which was almost double that of the specified target.
  • In 2019 we undertook our first independent GMO vaccine, Phase 2, Class 1 study for patient undergoing Kidney Transplantation.  Our previous experience of GMO vaccine trials has been through collaborations with our associated Medical School/University.
  • The PuraStat® post-market study into a device used to manage bleeding in vascular surgery patients recruited nearly triple the noted target within a 9-month period.

Our current Trust performance data can be viewed here

Our Workforce

Our research workforce has a robust and varied skill set each with their own areas of specialism.

  • Dedicated Pharmacy Clinical Trials Team (3 members of staff)
  • Dedicated Laboratory Clinical Trials Team (2 members of staff)
  • Established links and access to the Trust's Radiology and Cardiorespiratory Departments
  • We have more than 100 experienced Principle Investigators in the Trust
  • Dedicated team of Research Nurses, Clinical Trials Assistants and Research Practitioners

Quality Assurance

We also host an in-house R&D Quality Assurance team who are available to offer advice or internal monitoring to the Research Team to ensure a high quality of study delivery and data quality.

Further Information

If you would like us to conduct preliminary feasibility or if you have any other questions about collaborating with York and Scarborough Teaching Hospitals NHS Foundation Trust, please contact our Commercial Research Manager.

Dr Marthe Ludtmann

Tel: 07747763555




1st April 2023 – 31st March 2024

York & Scarborough

50 research studies open to recruitment


3246 patients recruited into clinical trials